ClinicalTrials.gg
Enrolling by invitationNCT07290764Updated Dec 18, 2025

Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy

An observational study in Hepatocellular Carcinoma, sponsored by Fujian Provincial Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Fujian Provincial Hospital · Observational

How we know · 2 judgments

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
729
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,314 studies in Carcinoma, Hepatocellular with a site in China — 489 open to participants now, 561 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Planned enrollment
75th of 275
729 · median 300
Started
2025
with 122 others
Observational
275 of 1,314
120 open now
Primary completion
2026-03
later than 217 of 560 live
Registered
1,172nd of 1,314
by date

Among the 1,314 studies in Carcinoma, Hepatocellular with a site in China, this one is the 75th largest by planned enrollment of the 275 observational ones that give a count, is one of 123 that started in 2025, is one of 275 observational ones, reaches primary completion later than 217 of the 560 other live ones, and was the 1,172nd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

489 of the 1,314 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

484 more — sign in →

All 489 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,314 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

This study aims to further explore the survival benefits of surgical resection after achieving CR in initial uHCC after systemic treatment and the timing of discontinuing systemic treatment

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with initially unresectable hepatocellular carcinoma, the tumor response reached complete remission after systematic treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged between 18 and 75
  2. : A/B grade
  3. score: ≤1 point
  4. The clinical or pathological diagnosis is consistent with primary HCC, and it has been evaluated by two senior hepatobiliary surgeons as surgically unresectable (including multiple intrahepatic lesions, local vascular invasion, local lymph node , and distant metastasis).
  5. According to the criteria, the patient has at least one (the long diameter of the measurable lesion on CT/MRI scans is ≥10mm, and the measurable lesion has not previously received local treatments such as interventional therapy, radiotherapy, or cryotherapy)
  6. Patients who achieved CR in tumor response after conversion therapy (based on systemic therapy) (rCR definition: The lesion is completely necrotic as evaluated by enhanced CT/MRI according to the mRECIST criteria;cCR is defined as: reaching rCR according to mRECIST criteria, having no distant metastatic lesions, normal AFP and DCP indicators, and maintaining the above criteria for ≥4weeks); Moreover, it can be surgically removed, with no for surgery or anesthesia
  7. The expected survival time is more than three months
  8. The functional indicators of important organs should meet the following requirements: · Blood routine: ≥ 1.5 × 109/L, ≥ 9.0 g/L, ≥ 75 × 109/L; · Liver function: Total ≤ 1.5 times the value (ULN) (for those with obstructive jaundice, after biliary drainage, it should be ≤ 2.5 times ULN); (ALT), Aspartate aminotransferase (AST) ≤ 5 times ULN, Albumin ≥ 30 g/L; · Kidney function: Serum creatinine ≤ 1.5 mg/dL, rate ≥ 60 ml/min; · Coagulation function: (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 times ULN.
  9. No history of severe arrhythmia, heart failure, etc. There is no history of severe ventilation dysfunction or serious pulmonary infection
  10. Fertile women should agree to use measures during the medication period and for 6 months after the medication is stopped; within 7 days before the study enrollment, the serum or urine pregnancy test must be negative, and the patient must be non-lactating. For male patients, they should agree to use contraceptive measures during the study period and for 6 months after the study is over

Exclusion criteria

Exclusion Criteria:

  1. Those who have had other malignant tumor histories within the past 5 years or simultaneously, but have been cured, such as skin basal cell carcinoma, cervical carcinoma in situ, and thyroid papillary carcinoma, are excluded
  2. Patients who have received organ transplants in the past or are planning to receive organ transplants
  3. Patients with any active diseases or those with autoimmune diseases and expected recurrence (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes)
  4. Have a history of immune deficiency; Patients who are currently undergoing or systemic hormone therapy to achieve immunosuppressive effects and are still using them within two weeks prior to signing the form
  5. Known hereditary or acquired bleeding disorders (such as coagulation dysfunction) or thrombosis tendencies, such as in patients with hemophilia; currently using or having used full-dose oral or injectable anticoagulant or thrombolytic drugs for therapeutic purposes (allowing for the preventive use of low-dose aspirin or low-molecular-weight heparin within 10 days prior to the start of the study treatment)
  6. Within 4 weeks prior to the first use of the drug, there was a severe infection, such as severe pneumonia requiring hospitalization, bacteremia, infection complications, etc.; the baseline chest imaging examination indicated active pulmonary inflammation; within 2 weeks prior to the first use of the investigational drug, there were symptoms and signs of infection or the need for oral or intravenous antibiotic treatment (excluding the use of antibiotics for prophylaxis)
  7. Patients with concurrent mental disorders; Has a history of abuse of psychotropic drugs, alcoholism and drug abuse
  8. Pregnant or lactating women
  9. Those who, as determined by the researchers, are not suitable to participate in this trial for other reasons
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
729 participants (estimated)
Patient registry
No

Groups and cohorts

  • Surgical Resection

    Patients who with initially unresectable hepatocellular carcinoma achieved complete response after conversion therapy received surgical resection

    Procedure: Surgery

  • Observation

    Patients who with initially unresectable hepatocellular carcinoma achieved complete response after conversion therapy didn't receive surgical resection

Interventions

  • ProcedureSurgery

    Surgical Resection Versus Observation in Patients with Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response After Systemic Therapy

06

What researchers measure

Primary outcomes

  1. three-year OS rate

    The ratio of the number of survivors from the start of systemic treatment until 3 years to the initial enrollment

    Time frame: "From date of enrollment until the date of date of death from any cause, assessed up to 100 months"

Secondary outcomes

  1. progression-free survival

    The period from the initiation of systemic treatment until disease progression, death or loss to follow-up

    Time frame: "From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months"

  2. Overall survival

    The time from the start of systemic treatment until death or loss to follow-up

    Time frame: From date of enrollment until the date of death from any cause, assessed up to 100 months

  3. Treatment-related adverse events

    The incidence rate, occurrence spectrum and severity of adverse events (AE) and serious adverse events (SAE), as well as the outliers of laboratory indicators, were judged according to the NCI-CTCAE V5.0 standard. Dose suspension rate and dose termination rate caused by adverse events

    Time frame: From date of enrollment until the date of death from any cause, assessed up to 100 months

Other outcomes

  1. Time to drug-off

    The time from the initiation of systemic treatment to the assessment of clinical complete response of the tumor and the subsequent discontinuation of systemic treatment

    Time frame: From date of enrollment until the date of drug-off or death from any cause, which come first, assessed up to 100 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — The data that support the findings of this study are not publicly available due to privacy reasons but are available from the corresponding author upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Mar 2026, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2025
First posted
Dec 18, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Mar 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07290764
Lead sponsor
Fujian Provincial Hospital
Responsible party
Mao-Lin Yan (professor, Fujian Provincial Hospital) — Principal investigator
First posted
Dec 18, 2025
Start date
Dec 1, 2025
Primary completion
Mar 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Dec 18, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion